Bioarctic Ab Class B · OMXSTO:BIOA_B
Bioarctic Ab Class B — Q3 2020 Earnings Presentation
18 slides from Bioarctic Ab Class B's earnings presentation, Oct 14, 2020
Slide 1: Third Quarter Report January-September 2020
BIOARCTIC AB (PUBL) NASDAQ STOCKHOLM: BIOA B Third Quarter Report January-September 2020 Stockholm, October 14, 2020 Gunilla Osswald, PhD, CEO Oskar Bosson, VP Communications & IR BioArctic AB
Slide 2: Disclaimer
Disclaimer • This presentation has been prepared and produced by BioArctic AB (publ) (“BioArctic”) solely for the benefit of investment analysis of BioArctic and may not be used for any other purpose. Unless otherwise stated, BioArctic is the source for all data contained in this presentation. Such
Slide 3: BioArctic – a unique Swedish biopharma company
BioArctic – a unique Swedish biopharma company Improving life for patients with central nervous system disorders High unmet need for disease-modifying treatments for Alzheimer’s and Parkinson’s diseases creates large commercial opportunity World-class research and development driven organization wit
Slide 4: Q3 2020 highlights: Another Phase 3 study in Alzheimer's disease
Q3 2020 highlights Another Phase 3 study in Alzheimer’s disease General • Celebrated 3 years as a listed company BAN2401 • Recruitment of early Alzheimer patients for Clarity AD confirmatory Phase 3 study ongoing • Phase 2b open label extension study data presented at AAIC • Rapid reduction of amylo
Slide 5: Attractive and well-balanced project portfolio combines partner and proprietary projects
Attractive and well-balanced project portfolio combines fully- financed partner projects and cutting-edge proprietary projects Project Partner Discovery Preclinical Phase 1 Phase 2 Phase 3 ALZHEIMER’S DISEASE BAN2401 (Clarity AD) Eisai1 Early Alzheimer’s disease4 BAN2401 (AHEAD 3-45) Eisai1 Preclini
Slide 6: Long-standing and extensive partnerships
Long-standing and extensive partnerships Alzheimer’s disease Parkinson’s disease Partner track record Collaboration and license Partner track record Collaboration and license MEUR 63 MUSD 130 received World’s all-time best-selling received Discovered and developed medicine (BUSD 20) world’s best-sel
Slide 7: BAN2401: potential disease modifying antibody for Alzheimer's disease
BAN2401: potential disease modifying antibody for Alzheimer’s disease with positive Phase 2b results now in Phase 3 High unmet medical need BAN2401 unique profile BAN2401 has positive Phase 2b results No existing disease- Unique and targeted binding • Large trial: 856 early Alzheimer’s modifying tre
Slide 8: Broad BAN2401 clinical program – driven by BioArctic's partner Eisai
Broad BAN2401 clinical program – driven by BioArctic’s partner Eisai Disease stage Preclinical AD MCI Mild AD Moderate Severe FDA guideline Stage 1 Stage 2 Stage 3 Stage 4 Stage 5 Stage 6 AHEAD 3-45 Phase 3 Program – Clarity AD Phase 3 confirmatory ongoing study – ongoing • Eisai and ACTC started ne
Slide 9: ABBV-0805: potential disease modifying antibody for Parkinson's disease
ABBV-0805: potential disease modifying antibody for Parkinson’s disease with strong preclinical results now in Phase 1 High unmet medical need Unique profile Preclinical proof of concept No existing disease- Unique and targeted binding Reduction of neurotoxic alpha-synuclein modifying treatment prof
Slide 10: Continued progress in collaboration with AbbVie on alpha-synuclein
Continued progress in collaboration with AbbVie on alpha-synuclein Collaboration highlights ABBV-0805 advancing in clinical trials • ABBV-0805 targeting disease modification in December January February March Parkinson’s disease 2018 2019 2019 2019 2020 • Potential to expand to earlier stage Parkins
Slide 11: Early stage portfolio continues to develop well
Early stage portfolio continues to develop well Alzheimer’s disease Parkinson’s disease Other CNS disorders Blood-brain barrier Diagnostics technology Discovery stage Discovery stage Neurodegeneration Blood-brain barrier Diagnostics programs projects research technology platform • Continued • 4 full
Slide 12: Financial Summary
Financial Summary 12 BioArctic AB
Slide 13: Net revenues and operating profit Q3 2020
Net revenues and operating profit Q3 2020 Net Revenues (MSEK) OPEX by item (MSEK) Operating Profit/Loss (MSEK) 515 100 430 86 80 60 53 44 48 43 40 36 32 171 40 127 63 20 21 26 36 17 7 11 -11 -21 4 -38 -21 0 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2018 2019 2020 2018 2019 2020 Q4 Q1 Q2 Q3 Q4
Slide 14: Cash and net profit Q3 2020
Cash and net profit Q3 2020 Cash Balance (MSEK) Cash Flow From Operating Net Result (MSEK) 1 256 1 218 Activities (MSEK) 335 1 170 1 113 1 077 1 050 1 036 334 917 97 100 -36 -20 -9 -89 -49 -54 14 -8 -38 -21 -17 4 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2018 2019 2020
Slide 15: Upcoming news and closing remarks
Upcoming news and closing remarks 15 BioArctic AB
Slide 16: Upcoming news flow
Upcoming news flow Alzheimer’s disease Parkinson’s disease Other CNS disorders Blood-brain barrier Diagnostics technology BAN2401 (Eisai) ABBV-0805 (AbbVie) Neurodegeneration Blood-brain barrier Diagnostics • To present data at • Complete Phase 1 research technology platform • Continue international
Slide 17: BioArctic: With Patients in Mind
BioArctic: With Patients in Mind Built on science Projects in focus Value-driven leadership Great science Great projects Great people 17 BioArctic AB
Slide 18: Contact and next report
GUNILLA OSSWALD, CEO JAN MATTSSON, CFO OSKAR BOSSON, VP NEXT REPORT & IR COMMUNICATIONS & IR CONTACT • Next Report: Full year report Jan-Dec 2020 on February 4, 2021 • Contact: Oskar Bosson, VP Communications & IR +46 704 10 71 80 [email protected] To subscribe to financial reports/press releases and